相似文献
1
Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach.
J Clin Microbiol. 2004 May;42(5):2241-6. doi: 10.1128/JCM.42.5.2241-2246.2004.
2
Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.
World J Gastroenterol. 2010 May 14;16(18):2272-7. doi: 10.3748/wjg.v16.i18.2272.
3
Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.
J Clin Microbiol. 2007 Feb;45(2):303-5. doi: 10.1128/JCM.01997-06. Epub 2006 Nov 22.
4
Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria.
J Antimicrob Chemother. 2018 Aug 1;73(8):2034-2038. doi: 10.1093/jac/dky167.
5
Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK.
J Med Microbiol. 2009 Oct;58(Pt 10):1322-1328. doi: 10.1099/jmm.0.011270-0. Epub 2009 Jul 9.
6
Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.
Int J Antimicrob Agents. 2007 Apr;29(4):389-96. doi: 10.1016/j.ijantimicag.2006.11.007. Epub 2007 Feb 15.
7
Detection of point mutations in the gyrA gene of Helicobacter pylori isolates in Slovenia.
Hepatogastroenterology. 2009 May-Jun;56(91-92):925-9.
8
Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance.
J Gastroenterol Hepatol. 2012 Mar;27(3):493-7. doi: 10.1111/j.1440-1746.2011.06874.x.
9
Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France.
Antimicrob Agents Chemother. 2012 Jan;56(1):550-1. doi: 10.1128/AAC.05243-11. Epub 2011 Nov 7.
10
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
BMC Microbiol. 2016 Nov 4;16(1):256. doi: 10.1186/s12866-016-0873-6.
引用本文的文献
1
Comparative Genomic Analysis of Multi-Drug Resistant Sequence Type 235 Isolated from Sudan.
Microorganisms. 2023 May 29;11(6):1432. doi: 10.3390/microorganisms11061432.
2
Optimizing Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments.
Gut Liver. 2023 Sep 15;17(5):684-697. doi: 10.5009/gnl220429. Epub 2023 Feb 27.
3
Rapid Detection of Quinolone Resistance Mutations in of by Real-Time PCR.
Pathogens. 2022 Jan 3;11(1):59. doi: 10.3390/pathogens11010059.
4
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. doi: 10.1038/s41575-021-00449-x. Epub 2021 May 17.
5
Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy.
Antibiotics (Basel). 2020 Oct 21;9(10):723. doi: 10.3390/antibiotics9100723.
6
Hellenic consensus on infection.
Ann Gastroenterol. 2020 Mar-Apr;33(2):105-124. doi: 10.20524/aog.2020.0446. Epub 2020 Jan 7.
7
Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania.
Can J Gastroenterol Hepatol. 2019 Jul 1;2019:8481375. doi: 10.1155/2019/8481375. eCollection 2019.
8
Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.
Front Mol Biosci. 2014 Oct 24;1:19. doi: 10.3389/fmolb.2014.00019. eCollection 2014.
9
Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France.
Antimicrob Agents Chemother. 2012 Jan;56(1):550-1. doi: 10.1128/AAC.05243-11. Epub 2011 Nov 7.
10
Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.
World J Gastrointest Pathophysiol. 2011 Jun 15;2(3):35-41. doi: 10.4291/wjgp.v2.i3.35.
本文引用的文献
1
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Dig Liver Dis. 2003 Apr;35(4):232-6. doi: 10.1016/s1590-8658(03)00059-8.
2
Levofloxacin based regimens for the eradication of Helicobacter pylori.
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1309-12. doi: 10.1097/00042737-200212000-00004.
3
Alternative and rescue treatment regimens for Helicobacter pylori eradication.
Expert Opin Pharmacother. 2002 Sep;3(9):1301-11. doi: 10.1517/14656566.3.9.1301.
4
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80. doi: 10.1046/j.1365-2036.2002.01169.x.
5
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.
Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):820-3. doi: 10.1007/s100960100611.
6
Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori.
Antimicrob Agents Chemother. 2001 Mar;45(3):727-33. doi: 10.1128/AAC.45.3.727-733.2001.
7
Genetic variability within Helicobacter pylori.
Int J Med Microbiol. 2000 May;290(2):175-81. doi: 10.1016/S1438-4221(00)80087-9.
8
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Aliment Pharmacol Ther. 2000 Oct;14(10):1339-43. doi: 10.1046/j.1365-2036.2000.00846.x.
9
Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.
Eur J Clin Microbiol Infect Dis. 2000 Jul;19(7):538-41. doi: 10.1007/s100960000288.
10
Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori.
Gastroenterology. 1998 Nov;115(5):1278-82. doi: 10.1016/s0016-5085(98)70101-5.
Zotero 插件